- Home
- AGIG vs TLPH Comparison
AGIG vs TLPH Comparison
Compare AGIG & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$0.97
Company Overview
Basic Information| Metric | AGIG | TLPH |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 64.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | AGIG | TLPH |
|---|---|---|
| Price | $3.61 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 967.4K | 329.5K |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $225,678.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.36 | $0.38 |
| 52 Week High | $12.70 | $1.57 |
Technical Indicators
Market Signals| Indicator | AGIG | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 37.16 |
| Support Level | $2.93 | $0.98 |
| Resistance Level | $3.55 | $1.01 |
| Average True Range (ATR) | 0.55 | 0.05 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 73.46 | 15.00 |
Price Performance
Historical Comparison AGIG
TLPH
About AGIG Abundia Global Impact Group Inc. Common stock
Abundia Global Impact Group Inc is a technology solutions company that operates in the recycling and renewable energy, environmental change, fuels and chemicals sectors. The company focuses on using waste products to decarbonize the energy, fuels and chemicals sector by providing renewable or recycled alternatives.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.